Synthesis produces hybrid compounds with enhanced antibacterial activities against S. aureus and E. coli, suggesting potential therapeutic applications.
In this study, we have developed new hybrid compounds by connecting bis‐heterocycles with a 2,3‐diphenoxyquinoxaline core. This is performed by combining 4,4′‐(quinoxaline‐2,3‐diylbis(oxy))dibenzaldehyde with the necessary reagents via Hantzsch and Biginelli reactions. The newly synthesized compounds' structures are determined by elemental analysis, 1 H NMR, 13 C NMR, IR, and MS spectra. The tested compound 18 has the strongest antibacterial activities against S. aureus and E. coli , with inhibition zones of 18 and 14.67 mm, respectively. The tested compound 5 exhibited the strongest antibacterial activities against S. aureus , with an inhibition zone of 17 mm. Molecular docking studies of the most efficient compounds were performed against two proteins, including ATP‐dependent Clp protease ATP‐binding subunit ClpA (UniProt ID: P0ABH9) and Glycerol dehydrogenase (GDH) (UniProt ID: P0A9S5). Compound 5 interacted with the ClpA active site, exhibiting a binding score of ∆G = −9.2 Kcal/mol, while 18 interacted with the GDH active site, exhibiting a binding score of ∆G = −11.4 Kcal/mol.
No takes yet. Share an insight, caveat, or question.
Diab et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: